Novartis AG

NOVN

CH0012005267

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 11:31:41 2025-07-08 am EDT			5-day change	1st Jan Change
97.71 ^CHF	+0.10%		+1.60%	+10.16%

Jul. 08	Pharma Stocks Pare Gains After Trump Reportedly Threatens 200% Tariff on Imported Drugs	MT
Jul. 08	Pharma Stocks Pare Gains After Trump Reportedly Threatens 200% Tariff on Imported Drugs	MT

Ahead of trade talks, Brussels seeks detail on firms' US spending

Published on 05/27/2025 at 11:23

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Novartis AG

Pharma Stocks Pare Gains After Trump Reportedly Threatens 200% Tariff on Imported Drugs	Jul. 08	MT
Pharma Stocks Pare Gains After Trump Reportedly Threatens 200% Tariff on Imported Drugs	Jul. 08	MT
Swiss Equities in the Green; Galderma Gains	Jul. 08	MT
Novartis wins approval for first malaria drug for newborns and babies	Jul. 08	RE
Global markets live: Apple, Honeywell Int., BP, Newmont, Nissan…	Jul. 08
Novartis wins approval for first malaria drug for newborns and babies	Jul. 08	RE
Novartis' Coartem Secures Swiss Approval as First Malaria Medicine for Newborns	Jul. 08	MT
Novartis Gets Swiss Approval for Malaria Drug for Infants	Jul. 08	MT
Novartis: pediatric antimalarial drug approved	Jul. 08	CF
Novartis gets Swissmedic approval for Coartem Baby as first malaria drug for newborns & young infants	Jul. 08	RE
Novartis' Malaria Treatment for Infants Receives Swissmedic Approval	Jul. 08	MT
Novartis receives approval for first malaria medicine for newborn babies and young infants	Jul. 08	DJ
Sector Update: Tech	Jul. 07	MT
Alphabet's Isomorphic Labs Readying to Test AI-Designed Drugs on People	Jul. 07	MT
GSK Finalizes Acquisition of Boston Pharmaceuticals' Liver Disease Drug Candidate	Jul. 07	MT
European shares fall as banks, mining stocks losses weigh	Jul. 04	RE
Swiss Market Index Closes Flat; Drugmakers Gain on US-Swiss Trade Deal Talks	Jul. 04	MT
NOVARTIS AG : Receives a Buy rating from Deutsche Bank	Jul. 04	ZD
European Equities Close Mostly Higher in Thursday Trading; EU Targets July 9 for US Trade Deal	Jul. 03	MT
Switzerland seeks trade deal with Trump without getting into EU bind	Jul. 03	RE
Swiss Market Index Closes Lower; Novartis Shares Down	Jul. 03	MT
NOVARTIS AG : UBS remains Neutral	Jul. 03	ZD
Novartis Drug Cosentyx Falls Short in Late-stage Trial for Giant Cell Arteritis	Jul. 03	MT
Novartis Says Cosentyx Fails to Meet Primary Endpoint in Phase 3 Giant Cell Arteritis Study	Jul. 03	MT
Novartis: Consentyx fails in Phase III	Jul. 03	CF

Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by therapeutic area as follows: - oncology (29.3%); - immunology (18.5%); - cardiovascular, renal and metabolic diseases (17%); - neuroscience (9.4%). The remaining net sales (25.8%) are from contract manufacturing of pharmaceutical products. At the end of 2024, Novartis AG had over 30 production sites worldwide. Net sales are distributed geographically as follows: Europe (30.9%), the United States (42%), Asia/Africa/Australasia (20%), Canada and Latin America (7.1%).

Employees

75,883

Sector

Pharmaceuticals

Calendar

Jul. 16 - Q2 2025 Earnings Release

More about the company